Is dupilumab/dalbitux a hormonal drug?

Dupilumab (dupilumab) is not a hormonal drug. It is a monoclonal antibody targeting interleukin-4 receptor α. It is a biological agent and does not have the ingredients or mode of action of corticosteroids. When many patients consider long-term treatment for eczema (atopic dermatitis), they are particularly worried about whether problems such as "hormone dependence" and "drug withdrawal rebound" will occur. However, the mechanism of dupilumab is completely different, so it does not fall into the category of hormone therapy in the traditional sense.

Hormone drugs such as glucocorticoids mainly improve symptoms by broadly suppressing the inflammatory response, but long-term use of high doses may cause risks such as skin thinning, telangiectasia, or affecting immune function. Dupilumab has a more precise path of action. It modulates the core "type II inflammatory response" in eczema by blocking the IL-4 and IL-13 signaling pathways, but it does not suppress the entire immune system like hormones do. This means that it is more suitable for maintaining the stable state of type II inflammatory diseases such as eczema, nasal polyps, asthma, etc. in long-term treatment.

In terms of usage experience, many patients often report that their skin condition gradually stabilizes and itching decreases when using Dalbitux, and there are no typical "hormonal side effects". Since it is not a hormone, there is no need to use it in layers or worry about skin weakness like topical hormones. For children, teenagers or patients with sensitive constitutions, precise intervention with biological agents can help reduce long-term dependence on external hormones and make the treatment rhythm more controllable.

In the entire type II inflammatory disease field, dupilumab is positioned as a "systemic targeted regulatory drug" that is responsible for improving the environment from the source of immunity, while hormones are short-term rapid suppression treatments. The two are completely different in positioning and mechanism. Patients can confirm the long-term plan and frequency of use with their doctor before receiving treatment, thereby establishing a more stable treatment expectation.

Reference materials:https://www.drugs.com